HeartWare shareholders have an opportunity to recover their investment losses. Click "Join this Class Action" above.
HeartWare International Inc.
Rosen Law Firm announces the filing of a securities class action lawsuit on behalf of purchasers of HeartWare International Inc. securities (NASDAQ: HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the “Class Period”), resulting from allegations that HeartWare may have issued materially misleading business information to the investing public.
If you purchased HeartWare stock from June 10, 2014 through January 11, 2016 and would like to join the action, please click "Join This Class Action" above.
EQUITY ALERT: Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against HeartWare International Inc. - HTWR
New York, N.Y., January 25, 2016. Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of HeartWare International Inc. securities (NASDAQ: HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
To join the HeartWare class action, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants falsely assured investors that HeartWare had adequately addressed numerous manufacturing and other regulatory failures at HeartWare’s sole manufacturing facility, and that the failures, which had been identified by the U.S. Food and Drug Administration (FDA) in a Warning Letter, posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing. When the true details concerning HeartWare’s failure to remediate the regulatory problems identified by the FDA and its impact on MVAD entered the market, HeartWare’s share price declined, causing investors damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827